Table 3 Provider-assessed adverse events
Provider-Assessed AE | CTCAE Grade | Baseline (n = 76) | Post-RT (n = 76) | 3 month (n = 72) | 12 month (n = 51) |
|---|---|---|---|---|---|
Dermatitis | 1 | 0% | 68% | 12% | 0% |
Skin Hyper-pigmentation | 1 | 3% | 12% | 18% | 0% |
Telangiectasia | 1 | 0% | 0% | 1% | 0% |
Superficial Fibrosis | 1 | 0% | 1% | 0% | 0% |
Deep fibrosis | 1 | 0% | 1% | 0% | 0% |
Seroma | 1 | 29% | 33% | 11% | 2% |
Chest pain | 1 | 0% | 5% | 4% | 0% |
Breast Edema | 1 | 1% | 22% | 8% | 2% |
Pneumonitis | Any | 0% | 0% | 0% | 0% |
Breast Infection | Any | 0% | 0% | 0% | 0% |